OMFIF LIMITED
Company number 07032533 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: B (Provisional)
Explanation: OMFIF LIMITED presents with excellent administrative and structural vital signs, showing a robust "immune system" against compliance failures. However, a complete financial diagnosis is currently impossible because the quantitative "blood work" (the actual financial figures from the balance sheet and profit & loss account) is missing from the patient's chart. The provisional grade of 'B' reflects strong corporate governance and compliance health, but this grade could shift significantly—up or down—once the underlying financial metrics are examined.
Key Vital Signs
- Pulse & Temperature (Compliance & Status): Strong and steady. The company is actively registered, not in liquidation, and has no overdue filings. Both the annual accounts and the confirmation statement are up to date, with the next accounts not due until late 2027. Filing "Full" accounts rather than abbreviated ones indicates a willingness to provide transparency, which is a sign of corporate vitality.
- Anatomical Structure (Governance & PSC): Well-formed. The board of directors is diverse and well-structured, including international representation (British, Australian, Singaporean), which aligns perfectly with its global focus as an independent forum for central banking. There is a clear Person with Significant Control (Mr David Wayne Marsh, owning 25-50%), meaning the ultimate control is transparent and localized, reducing the risk of sudden, unpredictable governance shocks.
- Bone Density (Capital Structure): Unusually light. The share capital is a mere £0.002 (a fraction of a penny). While this might look like a symptom of undernourishment, it is actually a common structural quirk in professional services and forum organizations. It means the business relies on retained earnings and operational cash flow to sustain itself, rather than heavy equity injections.
- Missing Blood Work (Financial Metrics): Absent. Without the turnover, net assets, current liabilities, and cash position, we cannot measure the company's financial blood pressure or cholesterol.
Diagnosis
Based on the observable symptoms, OMFIF LIMITED is an established, well-managed corporate entity. Having been incorporated in 2009, it has survived multiple economic cycles, indicating a resilient underlying business model. Operating from a prestigious City of London address (Snow Hill) and existing within the niche, high-level policy space (SIC 63990: Other information service activities), the organization is clearly not a fly-by-night operation.
The lack of quantitative financial data means we cannot definitively rule out underlying financial distress. However, the qualitative indicators—a stable board, full accounts filing, and a clean compliance record—suggest a business that is likely managing its financial health responsibly. There are no external signs of gangrene, such as administration, receivership, or director disqualifications.
Recommendations
- Order the Blood Work: To move from a provisional to a definitive health grade, the latest filed balance sheet and profit & loss accounts must be examined. You should retrieve the full accounts from Companies House to assess working capital (net current assets) and retained earnings (P&L reserve). This will reveal if the company has a healthy cash flow or is operating on financial life support.
- Monitor the Heart Rate (Cash Flow): Given the micro-sized share capital (£0.002), the company's lifeblood is its operational cash flow. Management should ensure that liquidity is continuously monitored, especially since policy forums can be subject to fluctuating sponsorship and membership revenues.
- Maintain Preventative Care: The current compliance and governance regime is excellent. Continue filing full accounts on time and maintaining a diverse, active board to ensure the corporate immune system remains robust against regulatory scrutiny.